RAS Mutation clinical trials at UCSF
2 in progress, 1 open to eligible people
A ras mutation is a change in a gene that can lead to cancer. UCSF is studying a new drug called ABM-168 to see if it is safe and works for people with advanced solid tumors. This trial is in its first phase and involves multiple centers.
ABM-168 in Adults With Advanced Solid Tumors.
open to eligible people ages 18 years and up
This is a Phase 1, First-in-Human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ABM-168 in adult patients with RAS or RAF or NF-1 mutated advanced solid tumors as ABM-168 may have a significant effect in inhibiting cell growth.
San Francisco, California and other locations
NAUTILUS: OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)
Sorry, in progress, not accepting new patients
The NAUTILUS study is a Phase 1b/2, multi-center, open-label study in which patients with activating mutations in the RAS pathway (Phase 1b) and patients with NRAS-mutated Melanoma (Phase 2) will be treated with a combination of oral OKI-179 combined with the MEK inhibitor binimetinib.
San Francisco, California and other locations
Our lead scientists for RAS Mutation research studies include Katy Tsai, M.D..
Last updated: